A Randomized, Open-Label, Phase III Study Of TARLATAMAB Compared With Standard Of Care ( LURBINECTEDIN ... ) In Subjects With Relapsed Small Cell Lung Cancer After Platinum-Based First-Line Chemotherapy .
| Actual Study Start Date : | May 31, 2023 | |
| Estimated Primary Completion Date : : | August 1, 2027 | |
| Estimated Study Completion Date : | August 1, 2027 |
Brief Summary :
The Main Objective Is To Compare The Efficacy Of TARLATAMAB With Standard Of Care ( SOC ) on Prolonging Overall Survival ( OS ) .
| Condition or disease | Intervention/treatment | Phase III |
|---|---|---|
| Small Cell Lung Cancer (SCLC) | Drug: TarlatamabDrug: LurbinectedinDrug: TopotecanDrug: Amrubicin |